This Medudy course is a video podcast for physicians on the
topic “Primary vs. Interval Surgery in Advanced Ovarian Cancer.”
Prof. Dr. Sven Mahner and Prof. Dr. Fabian Trillsch discuss the role of surgical therapy in
advanced ovarian cancer on the sidelines of the
American Cancer Congress ASCO 2026. The focus is on current analyses of the
TRUST study comparing primary debulking surgery and neoadjuvant
chemotherapy with interval surgery, as well as the question of which clinical factors—
in particular a significant pleural effusion or pleural carcinomatosis—determine the optimal
treatment sequence.
In addition, the two experts analyze German real-world data from the
QS-Ovar quality assurance database and derive practice-relevant recommendations
regarding patient selection, the importance of specialized centers, and the interaction
between surgery and systemic therapy.
By the end of this continuing education session, you will be familiar with:
– the key findings of the TRUST study comparing primary surgery and neoadjuvant chemotherapy with interval surgery in advanced
ovarian cancer.
– the significance of a significant pleural effusion or pleural carcinomatosis as a clinical selection parameter for choosing between primary and interval surgery.
– the role of surgical quality and treatment in specialized centers for patient outcomes.
– the most important findings from the German QS-Ovar real-world data on treatment distribution and survival, particularly the importance of combined surgical and systemic therapy.
– the criteria for assessing operability and the significance of imaging and surgical exploration in individualized treatment planning.
